Tarsus Pharmaceuticals (TARS) Share-based Compensation (2019 - 2026)

Tarsus Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 72.68% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $46.8 million (up 59.97% YoY), while the FY2025 annual figure was $41.7 million, up 49.97% from the prior year.
• Share-based Compensation was $12.0 million for Q1 2026 at Tarsus Pharmaceuticals, down from $14.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.3 million in Q4 2025 to a low of $2.7 million in Q1 2022.
• Historically, Share-based Compensation has averaged $6.8 million across 5 years, with a median of $5.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 51.33% in 2022, then surged 93.35% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $3.7 million in 2022, then surged by 49.33% to $5.5 million in 2023, then jumped by 35.04% to $7.4 million in 2024, then soared by 93.35% to $14.3 million in 2025, then declined by 16.4% to $12.0 million in 2026.
• The last three Share-based Compensation figures came in at $12.0 million (Q1 2026), $14.3 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.